Physician profile
Howard L Offenberg
NPI 1164532925
$12,057.30
in general payments reported to CMS, 2019-2025
27 companies · $1,361 in 2025
The $1,361 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,133 · 2020: $1,391 · 2021: $1,538 · 2022: $2,210 · 2023: $2,699 · 2024: $1,725 · 2025: $1,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,715 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,714.77 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,950.86 | 2019-2025 | Otezla, Enbrel, Prolia |
| Ucb, INC. | $2,358.98 | 2019-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $974.06 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.90 | 2020-2025 | Ofev, Cyltezo |
| Abbvie INC. | $802.99 | 2019-2025 | |
| Janssen Biotech, INC. | $782.92 | 2020-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $715.47 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $452.58 | 2019-2021 | |
| Glaxosmithkline, LLC. | $399.93 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $298.29 | 2021-2023 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $266.13 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $193.38 | 2022-2023 | Lupkynis |
| Horizon Therapeutics Plc | $174.41 | 2019-2023 | Krystexxa |
| Genentech USA, INC. | $167.27 | 2019-2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $141.74 | 2020-2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $141.09 | 2019-2021 | |
| Sobi, INC | $66.49 | 2019-2023 | |
| Antares Pharma, INC. | $62.55 | 2019-2020 | |
| Octapharma USA, INC. | $52.36 | 2024-2025 | Octagam Immune Globulin (Human) |
| Mallinckrodt Enterprises LLC | $44.95 | 2019 | |
| Ani Pharmaceuticals, INC. | $43.64 | 2024 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $40.59 | 2022-2024 | Strensiq |
| Ultragenyx Pharmaceutical INC. | $21.36 | 2024 | Crysvita |
| Organon LLC | $18.24 | 2021 | |
| Fresenius Kabi USA, LLC | $18.04 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $16.72 | 2021 | |
| Hikma Pharmaceuticals USA | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Offenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.